Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck 4Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Merck 4Q Results

Keytruda sales reach $7.8 billion in the quarter, up 19%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Merck

Image: Merck

Merck

4Q Revenues: $15.6 billion (+7%)

4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23)

FY Revenues: $64.2 billion (+7%)

FY Earnings: $17.1 billion (earnings were $365 million FY23)

Comments: Keytruda sales were $7.8 billion in the quarter, up 19%, driven by continued global demand from metastatic indications, including increased uptake in bladder and endometrial cancers, as well as increased global uptake in earlier-stage indications, including triple-negative breast cancer and non-small cell lung cancer.

Gardasil sales were down 17% to $1.6 billion, primarily due to lower demand in China. Proquad, MMR II, and Varivax sales were up 9% to $594 million, primarily due to higher pricing in the U.S. Vaxneuvance sales were down 9% to $161 million primarily driven by lower demand in the U.S. due to competition.

Januvia sales were $487 million in the quarter, down 38% primarily due to lower pricing in the U.S., as well as ongoing generic competition in many international markets. Bridion sales were up 5% to $449 million primarily due to higher demand in the U.S., partially offset by generic competition in certain international markets. Lynparza sales were up 16% to $365 million primarily due to higher global demand.

4Q23 results included charges related to the Daiichi Sankyo collaboration. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics